Search

Ibopamine

MUC1 Dendritic Cell Vaccine

The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

Atractylodes japonica root oil

It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation. … Atractylodes japonica root oil is obtained from the roots of Atractylodes japonica, which is a herb native to eastern Asia.

OSI-7836

It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested. … OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine.

Ramosetron

Currently, ramosetron is only approved for use Japan and in certain Southeast Asian countries. … Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions.

Mosedipimod

Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

Copper Cu-64

[T604] It is used in molecular radiotherapy and positron emission tomography. … Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.

Ostabolin-C

Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

IDM-4

IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

TGAAC94

It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]